AdAlta Ltd (ASX:1AD) has further bolstered its patent portfolio with a second US patent for its AD-214 treatment from the company’s flagship i-body platform, granted by the US Patent and Trademark Office.
This second US patent adds to those already secured for Australia and Japan. The company is further pursuing patents in major markets, including Europe and China.
The awarded patent, Number 11,142,588, is entitled 'Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer' and is directly tied to AdAlta’s first US patent, Number 10,538,596, with the same expiration date of January 8, 2036.
Intellectual property essential
AdAlta CEO and managing director Dr Tim Oldham said: “This second patent strengthens AdAlta’s patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world.
“Strong intellectual property protection is essential to our partnering and commercialisation strategy.”
This new patent protects the i-body sequence used in AdAlta’s lead product, AD-214, sequences similar to this and pharmaceutical compositions containing these i-body sequences.
Their uses in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF) – the lead indication for which AD-214 is being developed – are also covered by the patent.
AdAlta’s i-body platform
AdAlta is a clinical-stage drug development company headquartered in Melbourne, Australia. The company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.
The i-body technology mimics the shape and properties of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein.
The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases.
i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.